146 related articles for article (PubMed ID: 38858300)
1. Comparation of fixed-ratio (IDegLira and iGlarLixi) versus free combination of basal insulin and glucagon-like peptide-1 receptor agonist for uncontrolled type 2 diabetes: A systematic review and network meta-analysis.
Weng J; Tao Y; Xu Z; Zhou S; Xiao D; Zhu Z; Zheng R; Yang Y; Chen Y
J Evid Based Med; 2024 Jun; 17(2):370-376. PubMed ID: 38858300
[TBL] [Abstract][Full Text] [Related]
2. Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison.
Jung HN; Cho YK; Min SH; Kim HS; Kim YJ; Park JY; Lee WJ; Jung CH
Front Endocrinol (Lausanne); 2022; 13():870722. PubMed ID: 35669682
[TBL] [Abstract][Full Text] [Related]
3. An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin.
Evans M; Billings LK; Håkan-Bloch J; Slothuus U; Abrahamsen TJ; Andersen A; Jansen JP
J Med Econ; 2018 Apr; 21(4):340-347. PubMed ID: 29164973
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis.
Visolyi GÁ; Domján BA; Svébis MM; Péterfi A; Lovász BD; Mészáros S; Horváth VJ; Tabák ÁG
Can J Diabetes; 2023 Jun; 47(4):368-377. PubMed ID: 36963632
[TBL] [Abstract][Full Text] [Related]
5. Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis.
Liakopoulou P; Liakos A; Vasilakou D; Athanasiadou E; Bekiari E; Kazakos K; Tsapas A
Endocrine; 2017 Jun; 56(3):485-494. PubMed ID: 28401444
[TBL] [Abstract][Full Text] [Related]
6. Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Maiorino MI; Chiodini P; Bellastella G; Scappaticcio L; Longo M; Esposito K; Giugliano D
Diabetes Obes Metab; 2018 Sep; 20(9):2309-2313. PubMed ID: 29732679
[TBL] [Abstract][Full Text] [Related]
7. IDegLira for type 2 diabetes: a systematic review and meta-analysis.
Liu Y; Li X; Zheng Y; Wang X; Wang X
Endocrine; 2024 Mar; 83(3):648-658. PubMed ID: 37768513
[TBL] [Abstract][Full Text] [Related]
8. Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study.
Price H; Blüher M; Prager R; Phan TM; Thorsted BL; Schultes B;
Diabetes Obes Metab; 2018 Apr; 20(4):954-962. PubMed ID: 29205856
[TBL] [Abstract][Full Text] [Related]
9. The Clinical Use of a Fixed-Dose Combination of Insulin Degludec and Liraglutide (Xultophy 100/3.6) for the Treatment of Type 2 Diabetes.
Harris K; Nealy KL
Ann Pharmacother; 2018 Jan; 52(1):69-77. PubMed ID: 28799414
[TBL] [Abstract][Full Text] [Related]
10. Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes.
Østergaard L; Frandsen CS; Dejgaard TF; Madsbad S
Expert Rev Clin Pharmacol; 2017 Jun; 10(6):621-632. PubMed ID: 28349716
[TBL] [Abstract][Full Text] [Related]
11. Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis.
Caruso I; Di Gioia L; Di Molfetta S; Cignarelli A; Palmer SC; Natale P; Strippoli GFM; Perrini S; Natalicchio A; Laviola L; Giorgino F
EClinicalMedicine; 2023 Oct; 64():102181. PubMed ID: 37719418
[TBL] [Abstract][Full Text] [Related]
12. Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes.
Perreault L; Rodbard H; Valentine V; Johnson E
Adv Ther; 2019 Feb; 36(2):265-277. PubMed ID: 30610613
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.
Hunt B; Mocarski M; Valentine WJ; Langer J
J Med Econ; 2017 Jul; 20(7):663-670. PubMed ID: 28294641
[TBL] [Abstract][Full Text] [Related]
14. Transitioning from basal-bolus or premix insulin therapy to a combination of basal insulin and glucagon-like peptide-1 receptor agonist in people with type 2 diabetes.
Mehta R; Billings LK; Liebl A; Vilsbøll T
Diabet Med; 2022 Sep; 39(9):e14901. PubMed ID: 35708737
[TBL] [Abstract][Full Text] [Related]
15. Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature.
Lisco G; De Tullio A; Guastamacchia E; Triggiani V
Endocr Metab Immune Disord Drug Targets; 2021; 21(4):626-646. PubMed ID: 32628602
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis.
Singh S; Wright EE; Kwan AY; Thompson JC; Syed IA; Korol EE; Waser NA; Yu MB; Juneja R
Diabetes Obes Metab; 2017 Feb; 19(2):228-238. PubMed ID: 27717130
[TBL] [Abstract][Full Text] [Related]
17. Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes.
Risovic I; Dumanovic MS; Bojic M; Djekic D
BMC Endocr Disord; 2023 Feb; 23(1):28. PubMed ID: 36726134
[TBL] [Abstract][Full Text] [Related]
18. Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial.
Kaku K; Araki E; Tanizawa Y; Ross Agner B; Nishida T; Ranthe M; Inagaki N
Diabetes Obes Metab; 2019 Dec; 21(12):2674-2683. PubMed ID: 31407845
[TBL] [Abstract][Full Text] [Related]
19. Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database.
Anson M; Henney AE; Zhao SS; Ibarburu GH; Lip GYH; Cuthbertson DJ; Nabrdalik K; Alam U
Diabetes Obes Metab; 2024 Jul; 26(7):2606-2623. PubMed ID: 38558280
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison.
Home PD; Aroda VR; Blonde L; Guyot P; Shaunik A; Fazeli MS; Goswami H; Kalra S; Pourrahmat MM
Diabetes Obes Metab; 2020 Nov; 22(11):2170-2178. PubMed ID: 32627297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
